The FDA has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
- The approval was granted under a breakthrough therapy designation and marks the second
approved mRNA product from Moderna. The vaccine uses the same lipid nanoparticles (LNPs) as
the Moderna COVID-19 vaccines. - Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025
respiratory virus season.
Source: Moderna, Inc.
